Molecular imaging exploration of ocular angiogenic activity and evaluation of its value in therapeutic follow-up of AMD patients
Key facts
- Where
- Marseille, FranciaországSee the site
- Phase
- 2. fázis
Where in Franciaország
- Centre Hospitalier Regional De MarseilleMarseille, FranciaországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Regional De Marseille
- Trial code
- EU 2024-516970-31-00
- Record updated
- 2024. október 17.
- Original description
Evaluate the ability of 68Ga-NODAGA-RGD PET imaging to demonstrate, in 20 patients with unilateral AMD, a molecular therapeutic response to intraocular antiangiogenic injections at the end of the induction phase (after 3 months of treatment).Read full original descriptionShow less
Molecular imaging exploration of ocular angiogenic activity and evaluation of its value in therapeutic follow-up of AMD patients
Evaluate the ability of 68Ga-NODAGA-RGD PET imaging to demonstrate, in 20 patients with unilateral AMD, a molecular therapeutic response to intraocular antiangiogenic injections at the end of the induction phase (after 3 months of treatment).
Inclusion: Age ≥ 18 years; signed informed consent; Patient with unilateral AMD, with at least 1 focus of choroidal neovascularization on OCT, naïve to any antiangiogenic treatment; Initial check-up including at least OCT and visual acuity measurement, maximum 1 month old at the time of the 68Ga-NODAGA-RGD PET scan; affiliation to a social security scheme.
Exclusion: Patients previously treated with antiangiogenic therapy; Age ≤ 18 years; pregnant or breast-feeding women; Patients with bilateral AMD; Patients with AMD with no neovascularization focus as assessed by the standard diagnostic battery; Patients suffering from any other ophthalmological pathology; Monophtalmic patients.